Organigram Holdings Inc. (TSE:OGI - Free Report) - Analysts at Alliance Global Partners decreased their Q1 2025 earnings per share estimates for shares of Organigram in a research report issued on Wednesday, December 18th. Alliance Global Partners analyst A. Grey now forecasts that the company will earn ($0.05) per share for the quarter, down from their prior forecast of ($0.02). The consensus estimate for Organigram's current full-year earnings is $0.16 per share. Alliance Global Partners also issued estimates for Organigram's Q2 2025 earnings at ($0.04) EPS, Q3 2025 earnings at ($0.04) EPS, Q4 2025 earnings at ($0.04) EPS, FY2025 earnings at ($0.16) EPS and FY2026 earnings at ($0.11) EPS.
A number of other brokerages have also weighed in on OGI. ATB Capital lowered their target price on Organigram from C$5.25 to C$3.50 in a research note on Tuesday, December 17th. Canaccord Genuity Group lowered their price objective on shares of Organigram from C$3.60 to C$3.15 and set a "speculative buy" rating for the company in a research report on Monday, December 9th.
Get Our Latest Stock Analysis on Organigram
Shares of OGI opened at C$2.22 on Monday. The company has a debt-to-equity ratio of 1.13, a quick ratio of 2.62 and a current ratio of 6.95. The company has a market cap of C$241.03 million, a price-to-earnings ratio of -0.88, a PEG ratio of 0.42 and a beta of 1.13. The stock has a fifty day moving average price of C$2.26 and a two-hundred day moving average price of C$2.30. Organigram has a 52-week low of C$1.61 and a 52-week high of C$3.95.
In related news, Senior Officer Paolo De Luca sold 12,014 shares of the business's stock in a transaction that occurred on Thursday, October 24th. The shares were sold at an average price of C$2.52, for a total transaction of C$30,275.28. Insiders own 31.32% of the company's stock.
Organigram Holdings Inc, through its subsidiaries, engages in the production and sale of cannabis and cannabis-derived products in Canada. It offers medical cannabis products, including whole flower, milled flower, pre-rolls, infused pre-rolls, vapes, gummies, and concentrates for medical retailers; adult use recreational cannabis under the SHRED, Holy Mountain, Big Bag O' Buds, Monjour, Trailblazer, SHRED'ems, Edison Cannabis Co, Edison JOLTS, Tremblant, and Laurentian brands.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Organigram, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Organigram wasn't on the list.
While Organigram currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.